Portable Continuous Positive Airways Pressure (CPAP) in Excessive Central Airway Collapse (ECAC) Study

Sponsor
Papworth Hospital NHS Foundation Trust (Other)
Overall Status
Recruiting
CT.gov ID
NCT06072872
Collaborator
(none)
20
1
2
12.2
1.6

Study Details

Study Description

Brief Summary

This study will investigate the role of a portable Continues Positive Airway Pressure device (pCPAP) in management of patients with symptomatic Excessive Central Airway Collapse (ECAC). ECAC is characterised by complete or partial collapse of central airways on exhalation. In some cases, this can cause persistent breathlessness and severely limited exercise capacity. Current treatment options for ECAC are very limited. Standard assistive breathing devices such as CPAP machines are sometimes used to relieve symptoms at night or at rest. This does not address breathlessness during activity which drives accumulation of disability over time.

The main aims of this project are to assess the effect of a portable CPAP (pCPAP) device on exercise capacity and symptoms and evaluate the feasibility of wearing pCPAP at home during routine activities. Lightweight battery-powered portable CPAP devices have been recently developed to facilitate travel to remote areas by people with Obstructive Sleep Apnoea (OSA). Patients with ECAC can wear them during physical activity to prevent airway collapse but their potential benefits have not been evaluated in clinical trials.

For this study, the investigators will recruit 20 patients with ECAC who will attend for two study visits 4-6 weeks apart in a single centre (The Royal Papworth Hospital). The primary outcome measure will be a shuttle walk test performed repeatedly with and without pCPAP in a randomised order. Secondary outcomes will include assessment of activity level, breathlessness, quality of life ,pCPAP usage and its acceptability. The study will evaluate a pragmatic way of CPAP titration and application. Previously acquired diagnostic baseline computed tomography (CT) scans will be analysed with a novel Functional Respiratory Imaging (FRI) tool. This software tool will enable retrospective reflections on the changes occurring within the lungs for patients with ECAC. This may help identify predictive features of potential pCPAP responders and inform future use.

Condition or Disease Intervention/Treatment Phase
  • Device: Use of portable CPAP
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Intervention Model Description:
Prospective interventional, with first period without use of study device, followed with second period using study deviceProspective interventional, with first period without use of study device, followed with second period using study device
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Portable Continuous Positive Airways Pressure (CPAP) in Excessive Central Airway Collapse (ECAC) Study
Actual Study Start Date :
Jul 27, 2023
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Jul 31, 2024

Arms and Interventions

Arm Intervention/Treatment
No Intervention: No Portable CPAP

Patients continue life as normal without portable CPAP

Experimental: Use of portable CPAP

Patients use portable CPAP during periods of exercise

Device: Use of portable CPAP
Patients use portable CPAP during exercise

Outcome Measures

Primary Outcome Measures

  1. Distance achieved in incremental shuttle walk test with and without portable CPAP [After using portable CPAP for four weeks]

    Distance achieved in incremental shuttle walk test with and without portable CPAP after using portable CPAP

Secondary Outcome Measures

  1. Degree of dyspnoea pre and post shuttle walk test [During shuttle walk test performed after four weeks of using portable CPAP]

    dyspnoea will be measured using the Borg scale

Other Outcome Measures

  1. Activity levels with and without portable CPAP [30 day]

    Activity levels based on pedometer readings

  2. Average daily usage of CPAP [30 days]

    Absolute hours of daily usage

  3. Quality of life score [4 weeks]

    Respiratory-specific quality of life after use of portable CPAP using St George's Respiratory Questionnaire (scores range from 0 to 100, with higher scores indicating more limitations) and Severe Respiratory Insufficiency (SRI) questionnaire (score of 0 to 100 represents the worst to best health-related quality of life)

  4. Feasibility of CPAP self-titration [4 weeks]

    Feasibility and efficacy of CPAP self-titration using Likert scale (range 1-5, higher scores indicate better outcomes), change in CPAP pressure levels and distance walked whilst using portable CPAP

  5. participant perception of using portable CPAP [4 weeks]

    Participant acceptance of using CPAP and its perceived impact on activity level: assessed using a Likert scale ((range 1-5, higher scores indicate better outcomes)

  6. Correlation between severity of ECAC disease and response to portable CPAP [4 weeks]

    Correlation between severity of ECAC disease (as determined by FRI measurements in CT scans) and response to portable CPAP

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Diagnosis of ECAC based on >50% reduction of the antero-posterior diameter of large airways demonstrated on dynamic CT thorax or bronchoscopy. Only patients with tracheal and/or bilateral large bronchi (main to lobar) involvement will be included.

  2. Symptoms of dyspnoea felt to be predominantly caused by ECAC (where ECAC is the only respiratory pathology or dyspnoea is clearly out of proportion to a co-morbid respiratory condition)

  3. Medical Research Council (MRC) breathlessness scale of 3 (I stop for breath after walking about 100 yards or after a few minutes on level ground) or more.

  4. Age over 18 years

  5. Able to give informed consent -

Exclusion Criteria:
  • Patients with dynamic collapse of only segmental airways

  • Comorbidity which is likely to be an additional limiting factor in exercise tolerance

  • Contraindication to CPAP

  • Contraindication to incremental shuttle walk testing (ISWT), including; myocardial infarction within the last 3-5 days, unstable angina, uncontrolled arrhythmia, severe symptomatic cardiac or valvular disease, acute pulmonary embolus, uncontrolled asthma, syncope, mental impairment resulting in inability to perform test.

  • Resting oxygen saturations <90% on air or need for ambulatory oxygen therapy

  • Immobility that would make ISWT unfeasible

  • Severe emphysema

  • Acute infectious disease

  • Acute respiratory illness

Contacts and Locations

Locations

Site City State Country Postal Code
1 Royal Papworth Hospital Cambridge Cambridgeshire United Kingdom CB2 0AY

Sponsors and Collaborators

  • Papworth Hospital NHS Foundation Trust

Investigators

  • Principal Investigator: Dariusz Wozniak, MD, PhD, Royal Papworth Hospital NHS Foundation Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Papworth Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT06072872
Other Study ID Numbers:
  • P03038
First Posted:
Oct 10, 2023
Last Update Posted:
Oct 10, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 10, 2023